ZYUS Life Sciences Announces Positive Topline Results from Phase 2a UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug in Patients with Advanced Cancer

Phase 2positiveTrichomylin®Positive

AI Analysis

Summary

ZYUS Life Sciences reported positive topline results from the Phase 2a UTOPIA-1 trial of Trichomylin® softgel capsules for advanced cancer pain, demonstrating clinically relevant efficacy and favorable safety profile with no related serious adverse events.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Phase 2a UTOPIA-1 trial demonstrated clinically relevant efficacy signals using multiple pain assessments; well-tolerated with no related serious adverse events observed

Importance:7/10

Sentiment:

0.75

oncologypain managementnon-opioidPhase 2 datapositive resultssafety

Read the original article

Published by PR Newswire Biotech on October 1, 2026 12:09 PM

Read Original